PCGF2

Across TCGA pan-cancer cohorts, PCGF2 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of PCGF2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PCGF2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PCGF2 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

HNSC, BLCA, and COAD are the cancer types where PCGF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCGF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.112	<.001	12	view →
BLCA	All	III,IV	+0.991	<.001	10	view →
COAD	All	III,IV	+0.903	<.001	10	view →
LIHC	Female	II,III,IV	+1.847	<.001	9	view →
KIRC	Male	II,III,IV	−0.538	<.001	9	view →
STAD	Male	IV	+1.634	<.001	8	view →
KICH	Female	II,III,IV	−1.627	<.001	8	view →
KIRP	All	II,III,IV	+0.390	.001	8	view →
THCA	Female	All	+0.567	<.001	7	view →
BRCA	All	III,IV	+1.017	<.001	6	view →
LUSC	All	All	+0.351	<.001	6	view →
CHOL	Female	All	+3.023	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

PCGF2–HNSC

Open the HNSC breakdown →